A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML - Brian A. Jonas; Laura A. Potter; Maria Galkin; Joseph M. Tuscano (Leukemia Research Reports, 2023)